Kabuki-Za: Confirmation

EDINETMay 31 01:05 ET · Announcements

Kabuki-Za: Financial Report - 100th Term (2023/03/01 - 2024/02/29)

EDINETMay 31 01:03 ET · Announcements

Kabuki-Za: Extraordinary Report

EDINETMay 30 22:11 ET · Announcements

Astellas Pharmaceuticals, 24/3 revised downward operating profit 13 billion yen ← 83 billion yen

Astellas Pharmaceuticals ＜4503＞ announced revisions to its earnings forecast for the fiscal year ending 2024/3. Operating profit was revised downward from 83 billion yen to 13 billion yen. As a result of reviewing the asset value of the gene therapy program AT808, which is undergoing research and development for Friedreich ataxia patients, impairment losses of approximately 40 billion yen of intangible assets related to AT808 will be recorded as other expenses. [Positive Evaluation] ＜8233＞Takashimaya Full Year | ＜6432＞Takeuchi Production

Fisco JapanApr 14 17:23 ET

Kabuki Za Co Sees FY Net Y80.00M

Kabuki-Za Co. Ltd. also released the following forecasts: GROUP 1st Half To Year Ending Aug 2024 Feb 2025 Revenue Y1.50 bln Y2.98 bln Ope

Dow JonesApr 12 03:00 ET

Bic Camera, Money Forward, Ryohin Keikaku, Takashimaya (12 days)

*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------4/12 (Fri) ＜1401＞mbs ＜1407＞West HD＜1418＞Interlife ＜1434＞JESCOHD＜2153＞Ejay HD ＜2168＞Pasona G＜2305＞Studio Alice ＜2379＞dip

Fisco JapanApr 11 17:30 ET